Cure My Disease

Don't miss your cure!

 Log in / Sign up

One-Time cell therapy trial shows promise for Tough-to-Treat blood cancer

NCT ID NCT03568461

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study tested a one-time treatment called tisagenlecleucel, a type of CAR-T cell therapy, in adults whose follicular lymphoma had returned or stopped responding to other treatments. Doctors collected and reprogrammed each patient's own immune cells to better find and attack their cancer. The main goal was to see how well this personalized therapy worked and how safe it was over two years of follow-up.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Amsterdam UMC, locatie AMC

    Amsterdam, 1105 AZ, Netherlands

  • City of Hope National Medical Center

    Duarte, California, 91010 3000, United States

  • H Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida, 33612, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Michigan Med University of Michigan

    Ann Arbor, Michigan, 48109 5271, United States

  • Novartis Investigative Site

    Camperdown, New South Wales, 2050, Australia

  • Novartis Investigative Site

    Melbourne, Victoria, 3000, Australia

  • Novartis Investigative Site

    Herston, QLD 4006, Australia

  • Novartis Investigative Site

    Linz, 4020, Austria

  • Novartis Investigative Site

    Ghent, 9000, Belgium

  • Novartis Investigative Site

    Paris, 75475, France

  • Novartis Investigative Site

    Pierre-Bénite, 69495, France

  • Novartis Investigative Site

    Munich, Bavaria, 81377, Germany

  • Novartis Investigative Site

    Cologne, 50937, Germany

  • Novartis Investigative Site

    Ulm, 89081, Germany

  • Novartis Investigative Site

    Bologna, BO, 40138, Italy

  • Novartis Investigative Site

    Milan, MI, 20132, Italy

  • Novartis Investigative Site

    Fukuoka, Fukuoka, 812-8582, Japan

  • Novartis Investigative Site

    Sapporo, Hokkaido, 060 8648, Japan

  • Novartis Investigative Site

    Sendai, Miyagi, 980 8574, Japan

  • Novartis Investigative Site

    Amsterdam, North Holland, 1081 HV, Netherlands

  • Novartis Investigative Site

    Oslo, 0310, Norway

  • Novartis Investigative Site

    Seville, Andalusia, 41013, Spain

  • Novartis Investigative Site

    Madrid, 28041, Spain

  • Novartis Investigative Site

    Birmingham, B15 2TH, United Kingdom

  • Novartis Investigative Site

    London, SE5 9RS, United Kingdom

  • Oregon Health Sciences University

    Portland, Oregon, 97239, United States

  • UCSF Medical Center

    San Francisco, California, 94143, United States

  • Uni of Chi Medi Ctr Hema and Onco

    Chicago, Illinois, 60637, United States

  • Univ of Kansas Hosp and Med Ctr

    Kansas City, Kansas, 66160, United States

  • University of Pennsylvania Clinical

    Philadelphia, Pennsylvania, 19104, United States

Conditions

Explore the condition pages connected to this study.

FOLLICULAR LYMPHOMA